Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

First in class pharmacological solution for treatment of symptomatic vitreomacular adhesion and vitreomacular traction


JETREA® (ocriplasmin) is the first and only pharmacological treatment indicated for symptomatic vitreomacular adhesion and vitreomacular traction (sVMA/ VMT). Ocriplasmin is a truncated form of human plasmin. It is a small molecule designed for use in the eye that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface. First introduced in 2013, over 35,000 patients have been treated with Jetrea so far.

In March 2020, Oxurion and Inceptua Group signed a global commercial license agreement for Jetrea®. 

“Our worldwide license agreement with Inceptua will allow us to fully focus our organization and resources on further progressing our promising clinical pipeline of next generation non-VEGF assets for treatment of diabetic eye disease.”

Patrik De Haes, M.D., Non-Executive Chairman of Oxurion

Read full press release